Successful Strategies to Determine High-Resolution Structures of GPCRs

Trends in Pharmacological Sciences

Volumn 37, Issue 12, 2016, Pages 1055-1069

  Xiang, Jin ^a,b   Chun, Eugene ^a   Liu, Chang ^a   Jing, Liang ^a   Al Sahouri, Zina ^a   Zhu, Lan ^a   Liu, Wei ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

^b WUHAN UNIVERSITY   (China)

Author keywords

GPCRs; ligand binding; lipidic cubic phase; protein engineering; structure based drug discovery

Indexed keywords

DETERGENT; G PROTEIN COUPLED RECEPTOR; HYBRID PROTEIN; LIPID; LIGAND;

ALPHA HELIX; AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CHEMICAL PROCEDURES; CRYSTALLIZATION; GENE EXPRESSION SYSTEM; HIGH RESOLUTION STRUCTURE; HUMAN; LIGAND BINDING; LIPIDIC CUBIC PHASE; MUTAGENESIS; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN STABILITY; PROTEIN STRUCTURE; RECEPTOR AFFINITY; RECEPTOR BINDING; REVIEW; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; THERMOSTABILITY; ANIMAL; CHEMISTRY; HUMAN GENOME; METABOLISM; PHYSIOLOGY; PROCEDURES;

ANIMALS; CRYSTALLIZATION; GENOME, HUMAN; HUMANS; LIGANDS; LIPIDS; PROTEIN CONFORMATION; PROTEIN ENGINEERING; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84992170625     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2016.09.009     Document Type: Review

References (87)

1. 1 Ghosh, E., et al. Methodological advances: the unsung heroes of the GPCR structural revolution. Nat. Rev. Mol. Cell. Biol. 16 (2015), 69–81.
2. 2 Piscitelli, C.L., et al. A molecular pharmacologist's guide to G protein-coupled receptor crystallography. Mol. Pharmacol. 88 (2015), 536–551.
3. 3 Milic, D., Veprintsev, D.B., Large-scale production and protein engineering of G protein-coupled receptors for structural studies. Front. Pharmacol., 6, 2015, 66.
4. 4 Fang, Y., et al. Editorial: Orphan GPCRs as emerging drug targets. Front. Pharmacol., 6, 2015, 295.
5. 5 Fredriksson, R., et al. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol. 63 (2003), 1256–1272.
6. 6 Palczewski, K., et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289 (2000), 739–745.
7. 7 Park, J.H., et al. Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature 454 (2008), 183–187.
8. 8 Liu, W., et al. Structural basis for allosteric regulation of GPCRs by sodium ions. Science 337 (2012), 232–236.
9. 9 Fenalti, G., et al. Molecular control of delta-opioid receptor signalling. Nature 506 (2014), 191–196.
10. 10 Wu, H., et al. Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator. Science 344 (2014), 58–64.
11. 11 Lohse, M.J., et al. Kinetics and mechanism of G protein-coupled receptor activation. Curr. Opin. Cell Biol. 27 (2014), 87–93.
12. 12 Warne, T., et al. Structure of a beta1-adrenergic G-protein-coupled receptor. Nature, 454, 2008 486–391.
13. 13 Alexandrov, A.I., et al. Microscale fluorescent thermal stability assay for membrane proteins. Structure 16 (2008), 351–359.
14. 14 Kang, Y., et al. Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser. Nature 523 (2015), 561–567.
15. 15 Warne, T., et al. The structural basis for agonist and partial agonist action on a beta(1)-adrenergic receptor. Nature 469 (2011), 241–244.
16. 16 Huang, W., et al. Structural insights into mu-opioid receptor activation. Nature 524 (2015), 315–321.
17. 17 White, J.F., et al. Structure of the agonist-bound neurotensin receptor. Nature 490 (2012), 508–513.
18. 18 Xu, F., et al. Structure of an agonist-bound human A2A adenosine receptor. Science 332 (2011), 322–327.
19. 19 Lebon, G., et al. Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. Nature 474 (2011), 521–525.
20. 20 Rasmussen, S.G., et al. Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature 477 (2011), 549–555.
21. 21 Ring, A.M., et al. Adrenaline-activated structure of beta2-adrenoceptor stabilized by an engineered nanobody. Nature 502 (2013), 575–579.
22. 22 Wang, C., et al. Structural basis for molecular recognition at serotonin receptors. Science 340 (2013), 610–614.
23. 23 Wacker, D., et al. Structural features for functional selectivity at serotonin receptors. Science 340 (2013), 615–619.
24. 24 Kruse, A.C., et al. Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 504 (2013), 101–106.
25. 25 Zhang, J., et al. Agonist-bound structure of the human P2Y12 receptor. Nature 509 (2014), 119–122.
26. 26 Srivastava, A., et al. High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. Nature 513 (2014), 124–127.
27. 27 Wang, C., et al. Structural basis for Smoothened receptor modulation and chemoresistance to anticancer drugs. Nat. Commun., 5, 2014, 4355.
28. 28 Chun, E., et al. Fusion partner toolchest for the stabilization and crystallization of G protein-coupled receptors. Structure 20 (2012), 967–976.
29. 29 Tan, Q., et al. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 341 (2013), 1387–1390.
30. 30 Zhang, D., et al. Two disparate ligand-binding sites in the human P2Y1 receptor. Nature 520 (2015), 317–321.
31. 31 Yin, J., et al. Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant. Nature 519 (2015), 247–250.
32. 32 Yin, J., et al. Structure and ligand-binding mechanism of the human OX1 and OX2 orexin receptors. Nat. Struct. Mol. Biol. 23 (2016), 293–299.
33. 33 Thal, D.M., et al. Crystal structures of the M1 and M4 muscarinic acetylcholine receptors. Nature 531 (2016), 335–340.
34. 34 Granier, S., et al. Structure of the delta-opioid receptor bound to naltrindole. Nature 485 (2012), 400–404.
35. 35 Thompson, A.A., et al. Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature 485 (2012), 395–399.
36. 36 Cherezov, V., et al. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318 (2007), 1258–1265.
37. 37 Zhang, C., et al. High-resolution crystal structure of human protease-activated receptor 1. Nature 492 (2012), 387–392.
38. 38 Wu, H., et al. Structure of the human kappa-opioid receptor in complex with JDTic. Nature 485 (2012), 327–332.
39. 39 Zhang, K., et al. Structure of the human P2Y12 receptor in complex with an antithrombotic drug. Nature 509 (2014), 115–118.
40. 40 Huang, J., et al. Crystal structure of oligomeric beta1-adrenergic G protein-coupled receptors in ligand-free basal state. Nat. Struct. Mol. Biol. 20 (2013), 419–425.
41. 41 Wu, B., et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330 (2010), 1066–1071.
42. 42 Chien, E.Y., et al. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 330 (2010), 1091–1095.
43. 43 Hollenstein, K., et al. Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature 499 (2013), 438–443.
44. 44 Rasmussen, S.G., et al. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 450 (2007), 383–387.
45. 45 Burg, J.S., et al. Structural biology. Structural basis for chemokine recognition and activation of a viral G protein-coupled receptor. Science 347 (2015), 1113–1137.
46. 46 Shimamura, T., et al. Structure of the human histamine H1 receptor complex with doxepin. Nature 475 (2011), 65–70.
47. 47 Egloff, P., et al. Structure of signaling-competent neurotensin receptor 1 obtained by directed evolution in Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), E655–E662.
48. 48 Tobin, A.B., G-protein-coupled receptor phosphorylation: where, when and by whom. Br. J. Pharmacol. 153:Suppl 1 (2008), S167–S176.
49. 49 Nobles, K.N., et al. Distinct phosphorylation sites on the beta(2)-adrenergic receptor establish a barcode that encodes differential functions of beta-arrestin. Sci. Signal., 4, 2011, ra51.
50. 50 Zuckerman, D.M., et al. Differential regulation of two palmitoylation sites in the cytoplasmic tail of the beta1-adrenergic receptor. J. Biol. Chem. 286 (2011), 19014–19023.
51. 51 Grueninger-Leitch, F., et al. Deglycosylation of proteins for crystallization using recombinant fusion protein glycosidases. Protein Sci. 5 (1996), 2617–2622.
52. 52 Liu, W., Cherezov, V., Crystallization of membrane proteins in lipidic mesophases. J. Vis. Exp., 2011, e2501.
53. 53 Caffrey, M., A comprehensive review of the lipid cubic phase or in meso method for crystallizing membrane and soluble proteins and complexes. Acta Crystallogr. F Struct. Biol. Commun. 71:Pt 1 (2015), 3–18.
54. 54 Fenalti, G., et al. Fluorescence recovery after photobleaching in lipidic cubic phase (LCP-FRAP): a precrystallization assay for membrane proteins. Methods Enzymol. 557 (2015), 417–437.
55. 55 Hanson, M.A., et al. Crystal structure of a lipid G protein-coupled receptor. Science 335 (2012), 851–855.
56. 56 Cherezov, V., et al. Crystallization screens: compatibility with the lipidic cubic phase for in meso crystallization of membrane proteins. Biophys J. 81 (2001), 225–242.
57. 57 Kruse, A.C., et al. Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature 482 (2012), 552–556.
58. 58 Haga, K., et al. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 482 (2012), 547–551.
59. 59 Liu, W., et al. Preparation of microcrystals in lipidic cubic phase for serial femtosecond crystallography. Nat. Protoc. 9 (2014), 2123–2134.
60. 60 Liu, W., et al. Serial femtosecond crystallography of G protein-coupled receptors. Science 342 (2013), 1521–1524.
61. 61 Boess, F.G., Martin, I.L., Molecular biology of 5-HT receptors. Neuropharmacology 33 (1994), 275–317.
62. 62 Uustare, A., et al. Kinetic and functional properties of [3H]ZM241385, a high affinity antagonist for adenosine A2A receptors. Life Sci. 76 (2005), 1513–1526.
63. 63 Wexler, R.R., et al. Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. J. Med. Chem. 39 (1996), 625–656.
64. 64 Garcia-Perez, J., et al. New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection. J. Biol. Chem. 286 (2011), 4978–4990.
65. 65 Thoma, G., et al. Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo. J. Med. Chem. 51 (2008), 7915–7920.
66. 66 Levant, B., The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol. Rev. 49 (1997), 231–252.
67. 67 Siu, F.Y., et al. Structure of the human glucagon class B G-protein-coupled receptor. Nature 499 (2013), 444–449.
68. 68 Inoue, I., et al. Impaired locomotor activity and exploratory behavior in mice lacking histamine H1 receptors. Proc. Natl. Acad. Sci. U. S. A. 93 (1996), 13316–13320.
69. 69 Moulton, B.C., Fryer, A.D., Muscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPD. Br. J. Pharmacol. 163 (2011), 44–52.
70. 70 Peralta, E.G., et al. Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J. 6 (1987), 3923–3929.
71. 71 Dowling, M.R., Charlton, S.J., Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor. Br. J. Pharmacol. 148 (2006), 927–937.
72. 72 Yamasaki, T., et al. Radiosynthesis and preliminary evaluation of 4-[18F]fluoro-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylb enzamide as a new positron emission tomography ligand for metabotropic glutamate receptor subtype 1. Bioorg. Med. Chem. Lett. 21 (2011), 2998–3001.
73. 73 Dore, A.S., et al. Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain. Nature 511 (2014), 557–562.
74. 74 Fischetti, C., et al. Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24. Eur. J. Pharmacol. 614 (2009), 50–57.
75. 75 Skrzydelski, D., et al. Differential involvement of intracellular domains of the rat NTS1 neurotensin receptor in coupling to G proteins: a molecular basis for agonist-directed trafficking of receptor stimulus. Mol. Pharmacol. 64 (2003), 421–429.
76. 76 Cox, C.D., et al. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H -1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J. Med. Chem. 53 (2010), 5320–5332.
77. 77 Bach, P., et al. 5-alkyl-1,3-oxazole derivatives of 6-amino-nicotinic acids as alkyl ester bioisosteres are antagonists of the P2Y12 receptor. Future Med. Chem. 5 (2013), 2037–2056.
78. 78 Chao, H., et al. Discovery of 2-(phenoxypyridine)-3-phenylureas as small molecule P2Y1 antagonists. J. Med. Chem. 56 (2013), 1704–1714.
79. 79 Chackalamannil, S., et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J. Med. Chem. 51 (2008), 3061–3064.
80. 80 Sanna, M.G., et al. Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat. Chem. Biol. 2 (2006), 434–441.
81. 81 Hoch, L., et al. MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor. FASEB J. 29 (2015), 1817–1829.
82. 82 Karlstrom, S., et al. Substituted 7-amino-5-thio-thiazolo[4,5-d]pyrimidines as potent and selective antagonists of the fractalkine receptor (CX3CR1). J. Med. Chem. 56 (2013), 3177–3190.
83. 83 Hieble, J.P., et al. Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J. Med. Chem. 38 (1995), 3415–3444.
84. 84 Sabio, M., et al. Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: identification of active compounds. Bioorg. Med. Chem. Lett. 18 (2008), 5391–5395.
85. 85 Raynor, K., et al. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol. Pharmacol. 45 (1994), 330–334.
86. 86 Shahbazian, A., et al. Involvement of mu- and kappa-, but not delta-, opioid receptors in the peristaltic motor depression caused by endogenous and exogenous opioids in the guinea-pig intestine. Br. J. Pharmacol. 135 (2002), 741–750.
87. 87 Morse, M., et al. Ligand-directed functional selectivity at the mu opioid receptor revealed by label-free integrative pharmacology on-target. PLoS One, 6, 2011, e25643.